Fig. 4From: No preclinical rationale for IGF1R directed therapy in chondrosarcoma of boneRelative cell viability after 72Â hours of combination treatment with OSI-906 and Doxorubicin. OSI-906 does not sensitize the cells to doxorubicinBack to article page